Abstract：Objective To evaluate the correlation between the skeletal muscle loss with the toxicity and efficacy in advanced lung cancer patients. Methods 35 advanced lung cancer patients treated with platinum-based doublet chemotherapy were included in this study. Skeletal muscle mass was measured by the human body composition analyzer. And nutritional status of patients were assessed by the scored patient-generated subjective global assessment (PG-SGA). After 2 cycles chemotherapy, the change of nutritional status, incidence of complications, and prognosis were compared between the decrease group (skeletal muscle loss>2%) and the control group (skeletal muscle loss≤2%). Results Compared with before treatment, patients in the control group had significantly lower PG-SGA scores (5.55±4.01 vs 3.25±2.84, P<0.05) and significantly higher prealbumin levels [(23.62±5.53)g/L vs (27.45±5.26g/L, P<0.05] after 2 cycles of chemotherapy. Besides, we found that patients in the decrease group had significantly higher incidence of I degree anemia (35% vs 66%, P<0.05), II-III grade gastrointestinal reaction (35% vs 66%, P<0.05) and PD (5% vs 20%, P<0.05), and significantly lower incidence of PR (35% vs 13.3%, P<0.05) than in the control group. Conclusions The skeletal muscle loss>2% during chemotherapy could influence the incidence of side effects and efficacy, suggesting that it may serve as a predictor of side effects and prognosis of chemotherapy
姚克青，丛明华，代忠. 骨骼肌减少与肺癌毒性反应及化疗疗效相关性研究[J]. 肿瘤代谢与营养电子杂志, 2018, 5(1): 59-62.
1 YAO Ke-qing, 1 CONG Ming-hua, 2 DAI Zhong,. Skeletal muscle loss correlates toxic reaction and chemotherapy efficacy in patients with advanced lung cancer. Electronic Journal of Metabolism and Nutrition of, 2018, 5(1): 59-62.
